

Appendix

Members of FLASH

Figure A1. Patient Inclusion CONSORT

Table A1. Included Trial Summary

Table A2. Logistic Models for PFS24

Table A3. Survival Estimates using the definitions from the original NLCS paper

Members of FLASH

Member	Institution
Christopher R. Flowers	University of Texas MD Anderson Cancer Center, Houston, TX
Nathan H. Fowler	University of Texas MD Anderson Cancer Center, Houston, TX
Anton Hagenbeek	Academic Medical Center, Amsterdam, the Netherlands
Michael Herold	Leiter Onkologisches Zentrum
Wolfgang Hiddemann	Ludwig-Maximilians University Hospital, Munich, Germany
Eva Kimby	Karolinska Institute, Stockholm, Sweden
Marco Ladetto	Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Robert Marcus	HCA Healthcare London
Franck Morschhauser	Service Université de Lille 2, Lille, France
Gilles Salles	Memorial Sloan-Kettering Cancer Center, NY
Umberto Vitolo	Candiolo Cancer Institute, FPO-IRCCS, Torino, Italy
Emanuele Zucca	Swiss Group for Clinical Cancer Research, Bern, Switzerland
Daniel J. Sargent	Deceased; Mayo Clinic, Rochester, MN

Figure A1. Patient Inclusion CONSORT




Table A1. Included Trial Summary

Study Name	Reference	CT.gov Number	Regimen Used	Accrual Period	Patients
E1496	Hochster, 2009		MR vs. Obs after CVP		283
FL2000	Salles, 2008	NCT00136552	CHVP+I vs. R-CHVP+I	May 2000 - May 2002	358
GELF862	Solal-Celigny, 1993 Solal-Celigny, 1998 Bachy, 2010		CHVP vs. CHVP+I	Oct 1986 - Jun 1991	242
GELF942	Sebban, 2006		CHVP+I vs. CHOP+HDT	Jul 1994 - Mar 2001	401
GOELAMS064	Gyan, 2009	NCT00696735	CHVP vs. VCAP+ASCT	Apr 1994 - May 2001	166
GLSG2000	Hiddemann, 2005		CHOP vs. R-CHOP	May 2000 - Jun 2010	953
M39021	Marcus, 2008		CVP vs. CVP+R	Apr 2000 - Mar 2002	317
OSHO39	Herold, 2007		MCP vs. R-MCP	Oct 1998 - Sep 2003	341
ML16865	Kimby, 2015		R vs. R+IFN	Oct 2002 - Mar 2008	270
ML17638	Vitolo, 2013	NCT01144364	R vs Obs after R-FND	Jan 2004 - Dec 2007	229
GLSG1996	Nickenig, 2006		CHOP vs. MCP	May 1996 - Jul 2000	522
OSHO19	Herold, 2006		BOP vs. COP	Apr 1994 - Oct 1998	144
PRIMA	Salles, 2010	NCT00140582	R vs. Obs maintenance	Jan 2005 - Apr 2007	999

Table A2. Logistic Models for PFS24

	Induction Treatment Regimen											
	All Patients			R-Chemo Patients			Rituximab Patients			Chemo Patients		
	Events/Total	Odds Ratio (95% CI)	P-value	Events/Total	Odds Ratio (95% CI)	P-value	Events/Total	Odds Ratio (95% CI)	P-value	Events/Total	Odds Ratio (95% CI)	P-value
Tier 1	1524/4852			489/2252			121/265			914/2335		
Gender			<.0001 ²			0.0024 ²			0.6005 ²			0.0008 ²
Female	692/2383	Reference		220/1120	Reference		63/140	Reference		409/1123	Reference	
Male	832/2469	1.33 (1.18-1.51)	<.0001 ¹	269/1132	1.38 (1.12-1.69)	0.0024 ¹	58/125	1.14 (0.69-1.88)	0.6005 ¹	505/1212	1.34 (1.13-1.59)	0.0008 ¹
Performance Status			<.0001 ²			0.0031 ²			0.6770 ²			0.0009 ²
0-1	1379/4555	Reference		447/2136	Reference		117/258	Reference		815/2161	Reference	
>=2	145/297	1.82 (1.43-2.32)	<.0001 ¹	42/116	1.83 (1.23-2.73)	0.0031 ¹	4/7	1.39 (0.29-6.56)	0.6770 ¹	99/174	1.72 (1.25-2.37)	0.0009 ¹
FLIPI Risk Category			<.0001 ²			<.0001 ²			0.0172 ²			<.0001 ²
Low	158/846	Reference		54/383	Reference		11/39	Reference		93/424	Reference	
Intermediate	468/1793	1.52 (1.24-1.86)	<.0001 ¹	136/835	1.17 (0.83-1.65)	0.3728 ¹	33/80	1.86 (0.80-4.29)	0.1470 ¹	299/878	1.81 (1.38-2.37)	<.0001 ¹
High	898/2213	2.92 (2.40-3.54)	<.0001 ¹	299/1034	2.45 (1.78-3.37)	<.0001 ¹	77/146	2.90 (1.34-6.32)	0.0072 ¹	522/1033	3.54 (2.72-4.61)	<.0001 ¹
Tier 2	898/3088			410/1873			104/233			384/982		
Gender			0.0023 ²			0.0555 ²			0.4929 ²			0.0100 ²
Female	425/1560	Reference		192/940	Reference		55/126	Reference		178/494	Reference	
Male	473/1528	1.28 (1.09-1.51)	0.0023 ¹	218/933	1.25 (0.99-1.56)	0.0555 ¹	49/107	1.21 (0.71-2.06)	0.4929 ¹	206/488	1.43 (1.09-1.87)	0.0100 ¹
Performance Status			0.0057 ²			0.1595 ²			0.6284 ²			0.0264 ²
0-1	822/2916	Reference		379/1781	Reference		102/228	Reference		341/907	Reference	
>=2	76/172	1.58 (1.14-2.17)	0.0057 ¹	31/92	1.39 (0.88-2.21)	0.1595 ¹	2/5	0.63 (0.09-4.19)	0.6284 ¹	43/75	1.76 (1.07-2.88)	0.0264 ¹
FLIPI Risk Category			<.0001 ²			<.0001 ²			0.0175 ²			<.0001 ²
Low	79/517	Reference		49/338	Reference		8/34	Reference		22/145	Reference	
Intermediate	265/1132	1.61 (1.22-2.12)	0.0008 ¹	110/680	1.04 (0.72-1.50)	0.8395 ¹	27/68	2.22 (0.87-5.67)	0.0963 ¹	128/384	2.65 (1.60-4.39)	0.0001 ¹
High	554/1439	2.98 (2.28-3.91)	<.0001 ¹	251/855	1.89 (1.32-2.69)	0.0005 ¹	69/131	3.43 (1.42-8.24)	0.0060 ¹	234/453	5.45 (3.30-9.02)	<.0001 ¹
Beta-2 Value at Baseline			<.0001 ²			<.0001 ²			0.1509 ²			0.1711 ²
Normal	519/2123	Reference		217/1286	Reference		75/182	Reference		227/655	Reference	
Elevated	379/965	1.49 (1.25-1.77)	<.0001 ¹	193/587	1.90 (1.49-2.42)	<.0001 ¹	29/51	1.63 (0.84-3.16)	0.1509 ¹	157/327	1.23 (0.92-1.64)	0.1711 ¹

¹Covariate Wald p-value; ²Type 3 Wald p-value;

Table A3. Survival Estimates using the definitions from the original NLCS paper

Population	Group	2-year Estimates	5-year Estimates
All Patients	No-PD	96.3 (95.5-96.9%)	88.4 (87.1-89.6%)
	PD	69.1 (66.6-71.5%)	53.1 (50.3-55.8%)
R-Chemo	No-PD	97.4 (96.5-98.1%)	90.7 (89.0-92.2%)
	PD	74.2 (69.8-78.0%)	57.5 (52.5-62.3%)
Rituximab	No-PD	97.8 (93.3-99.3%)	95.6 (86.8-98.6%)
	PD	83.4 (75.4-89.0%)	75.7 (65.3-83.4%)
Chemo	No-PD	94.8 (93.5-95.8%)	85.3 (83.2-87.2%)
	PD	64.2 (60.8-67.4%)	47.6 (44.1-51.0%)